Healthcare • NASDAQ
According to Zyberno, Amphastar Pharmaceuticals, Inc. (AMPH) shows a Value Trap signal — GOOD BUSINESS (65/100) with an apparent Margin of Safety of +69.6%, but a Brina Gap of -5.1% reveals the current price still assumes faster growth than the business can deliver.
According to Zyberno's DCF model, Amphastar Pharmaceuticals, Inc. (AMPH) trades at $22.01 against an estimated intrinsic value per share of $72.44 — a +69.6% Margin of Safety based on Owner Earnings of $140.43M TTM, projected at 13.0% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -5.1% weakens the case: based on the company's ROIC (6.4%) and reinvestment rate (10.9%), the business can fundamentally grow at 0.7% — but the current enterprise value implies the market expects 5.8%. This places AMPH in the Value Trap quadrant of the Brina Matrix — a value-trap signal where the apparent discount is undermined by overpriced growth expectations. Zyberno's model translates this into a 5-year expected return of 43.4% annually.
Over the trailing twelve months, AMPH generated $140.43M in Owner Earnings. Capital was deployed as follows: $29.49M returned via share buybacks, $33.69M invested in capital expenditures. Reinvestment rate: 10.9%. Owner Earnings have grown at 13.0% annually over the trailing five years using log-linear regression.